Skip to main content
NVDA-0.32%AAPL+1.23%GOOGL-2.28%MSFT-0.03%AMZN+0.14%TSM-0.83%SPCX-3.86%AVGO-1.13%META+1.45%TSLA-0.53%SKHY+7.05%MU-1.52%BRK-B+0.18%LLY+0.02%JPM+0.34%AMD+3.04%WMT-0.21%V-0.34%XOM+2.24%ASMLa-1.48%JNJ-0.76%INTC+1.69%MA-0.59%0700.HK-1.94%ORCL-0.50%1398.HK+0.79%BAC+0.45%ABBV+0.88%CSCO+0.24%CVX+1.91%COST-0.83%LRCX-1.43%KO-0.92%CAT-0.84%AMAT-0.83%AP2d-0.80%0005.HK-0.78%HSBA.L-1.39%UNH-1.94%DELL+0.29%MS-0.42%PG-2.02%GE-2.83%3988.HK+0.84%1816.HK+0.23%0857.HK-3.26%NFLX-0.96%HD-1.04%GS-0.75%0939.HK+1.66%NZDJPY-2.15%CHFJPY-1.56%AUDJPY-1.47%USDJPY-1.41%EURJPY-1.28%CADJPY-1.26%GBPJPY-1.24%GBPNZD+0.91%EURNZD+0.90%NZDCAD-0.90%NZDUSD-0.77%AUDNZD+0.71%NZDCHF-0.61%USDNOK+0.47%EURNOK+0.43%GBPTRY+0.41%CHFNOK+0.37%USDZAR+0.34%GBPHKD+0.32%GBPCHF+0.31%EURZAR+0.30%GBPZAR+0.28%GBPMXN-0.28%CADCHF+0.28%EURCHF+0.27%AUDCAD-0.23%AUDNOK+0.22%USDTHB+0.22%AUDDKK-0.21%SGDJPY+0.21%USDSEK+0.21%GBPAUD+0.21%PLNJPY+0.19%EURAUD+0.19%GBPUSD+0.17%USDCHF+0.16%EURSEK+0.16%USDILS+0.16%NOKJPY-0.15%AUDSGD-0.15%USDPLN+0.14%USDCAD-0.13%USDMXN+0.12%EURUSD+0.12%USDSGD+0.12%USDTRY+0.11%CHFSEK+0.10%AUDCHF+0.10%EURPLN+0.09%NZDSGD+0.09%EURCZK-0.07%EURSGD+0.07%NZDMXN+0.07%AUDUSD-0.06%EURHKD-0.06%GBPSGD+0.05%USDDKK+0.05%USDCOP-0.04%EURCNH-0.03%EURGBP-0.03%EURCAD-0.02%USDHKD+0.01%GBPCAD+0.01%CHFSGD+0.01%USDCNH-0.01%EURDKK0.00%HG1-4.38%XPTUSD-2.78%COFFEE-2.45%GAGUSD-2.30%XAGUSD-2.30%SUGAR+1.72%COCOA-1.49%COTTON+0.97%C1+0.52%S1+0.50%GAUUSD-0.45%XAUUSD-0.45%BTCUSD-0.60%ETHUSD-0.21%USDTUSD-0.08%XRPUSD-1.49%SOLUSD-0.56%TRXUSDT+0.39%ZECUSDT-1.97%DOGEUSD-1.38%XMRUSDT-1.47%LINKUSD-0.25%XLMUSD-1.27%BCHUSDT-2.68%LTCUSD-1.75%UNIUSD-2.55%TONUSD+24.88%HBARUSDT-1.46%SUIUSD-1.76%TAOUSDT-1.43%AAVEUSD-2.26%DOTUSDT-2.54%ICPUSDT-1.62%ONDOUSDT-2.17%WLDUSDT-1.95%ATOMUSDT-2.92%ARBUSDT-1.26%JUPUSDT-2.96%INJUSDT-2.22%STXUSDT-3.25%FETUSDT-3.24%TIAUSDT-1.13%SEIUSDT-3.91%PYTHUSDT-1.26%IMXUSDT-3.06%WIFUSDT-3.42%GRTUSDT-3.02%OPUSDT-1.99%IOTAUSDT-3.10%POLUSDT-5.84%AXSUSDT-1.93%FARTCOINUSDT-2.66%EOSUSDT+0.31%DYDXUSDT-0.62%ORDIUSDT-0.64%GALAUSDT-3.09%NOTUSDT-0.68%RONINUSDT-0.71%NVDA-0.32%AAPL+1.23%GOOGL-2.28%MSFT-0.03%AMZN+0.14%TSM-0.83%SPCX-3.86%AVGO-1.13%META+1.45%TSLA-0.53%SKHY+7.05%MU-1.52%BRK-B+0.18%LLY+0.02%JPM+0.34%AMD+3.04%WMT-0.21%V-0.34%XOM+2.24%ASMLa-1.48%JNJ-0.76%INTC+1.69%MA-0.59%0700.HK-1.94%ORCL-0.50%1398.HK+0.79%BAC+0.45%ABBV+0.88%CSCO+0.24%CVX+1.91%COST-0.83%LRCX-1.43%KO-0.92%CAT-0.84%AMAT-0.83%AP2d-0.80%0005.HK-0.78%HSBA.L-1.39%UNH-1.94%DELL+0.29%MS-0.42%PG-2.02%GE-2.83%3988.HK+0.84%1816.HK+0.23%0857.HK-3.26%NFLX-0.96%HD-1.04%GS-0.75%0939.HK+1.66%NZDJPY-2.15%CHFJPY-1.56%AUDJPY-1.47%USDJPY-1.41%EURJPY-1.28%CADJPY-1.26%GBPJPY-1.24%GBPNZD+0.91%EURNZD+0.90%NZDCAD-0.90%NZDUSD-0.77%AUDNZD+0.71%NZDCHF-0.61%USDNOK+0.47%EURNOK+0.43%GBPTRY+0.41%CHFNOK+0.37%USDZAR+0.34%GBPHKD+0.32%GBPCHF+0.31%EURZAR+0.30%GBPZAR+0.28%GBPMXN-0.28%CADCHF+0.28%EURCHF+0.27%AUDCAD-0.23%AUDNOK+0.22%USDTHB+0.22%AUDDKK-0.21%SGDJPY+0.21%USDSEK+0.21%GBPAUD+0.21%PLNJPY+0.19%EURAUD+0.19%GBPUSD+0.17%USDCHF+0.16%EURSEK+0.16%USDILS+0.16%NOKJPY-0.15%AUDSGD-0.15%USDPLN+0.14%USDCAD-0.13%USDMXN+0.12%EURUSD+0.12%USDSGD+0.12%USDTRY+0.11%CHFSEK+0.10%AUDCHF+0.10%EURPLN+0.09%NZDSGD+0.09%EURCZK-0.07%EURSGD+0.07%NZDMXN+0.07%AUDUSD-0.06%EURHKD-0.06%GBPSGD+0.05%USDDKK+0.05%USDCOP-0.04%EURCNH-0.03%EURGBP-0.03%EURCAD-0.02%USDHKD+0.01%GBPCAD+0.01%CHFSGD+0.01%USDCNH-0.01%EURDKK0.00%HG1-4.38%XPTUSD-2.78%COFFEE-2.45%GAGUSD-2.30%XAGUSD-2.30%SUGAR+1.72%COCOA-1.49%COTTON+0.97%C1+0.52%S1+0.50%GAUUSD-0.45%XAUUSD-0.45%BTCUSD-0.60%ETHUSD-0.21%USDTUSD-0.08%XRPUSD-1.49%SOLUSD-0.56%TRXUSDT+0.39%ZECUSDT-1.97%DOGEUSD-1.38%XMRUSDT-1.47%LINKUSD-0.25%XLMUSD-1.27%BCHUSDT-2.68%LTCUSD-1.75%UNIUSD-2.55%TONUSD+24.88%HBARUSDT-1.46%SUIUSD-1.76%TAOUSDT-1.43%AAVEUSD-2.26%DOTUSDT-2.54%ICPUSDT-1.62%ONDOUSDT-2.17%WLDUSDT-1.95%ATOMUSDT-2.92%ARBUSDT-1.26%JUPUSDT-2.96%INJUSDT-2.22%STXUSDT-3.25%FETUSDT-3.24%TIAUSDT-1.13%SEIUSDT-3.91%PYTHUSDT-1.26%IMXUSDT-3.06%WIFUSDT-3.42%GRTUSDT-3.02%OPUSDT-1.99%IOTAUSDT-3.10%POLUSDT-5.84%AXSUSDT-1.93%FARTCOINUSDT-2.66%EOSUSDT+0.31%DYDXUSDT-0.62%ORDIUSDT-0.64%GALAUSDT-3.09%NOTUSDT-0.68%RONINUSDT-0.71%
EX

Exelixis, Inc. (EXEL)

NASDAQ • Healthcare

$58.33
+$0.65 (+1.1%)
Market closed

Last close at September 9, 2026 at 20:00 UTC

Open$57.6
Day Range$56.95 - $58.36
Avg. Volume (3M)2.1M
Market Cap$14.6B
P/E Ratio17.7
52 Week Range
$33.76$59.72
Next EarningsIn 54 daysNov 3, 2026

Metrics Over Time

Where the Money Goes

Q3 2026
Revenueeverything earned$628.6M100%
Gross Profitminus cost of goods$608M97%
Operating Incomeminus R&D and overhead$248.4M40%
Net Incomeminus taxes and the rest$212M34%

In plain terms: out of every $100 in revenue, Exelixis, Inc. keeps $34 as net profit.

Fundamentals & Financials

Revenue (TTM)
$2.4B
Net Income (TTM)
$860.6M
EPS (TTM)
$3.29
ROA (TTM)
34.5%
Current Ratio
3.46

TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.

Earnings

+22.1%Q1 2026$0.94
+13.7%Q2 2026$0.87
+6.7%Q3 2026$0.91
Next

Nov 3

in 54 daysQ4 2026

% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS

Latest report — Q3 2026
Beat +6.7%

Exelixis topped adjusted EPS expectations but revenue missed in the second fiscal quarter of 2026, reported Aug. 5, as adjusted EPS of $0.91 beat the $0.85 estimate by 6.7% while revenue of about $628.7 million fell short of the $636.4 million consensus by 1.2%. Revenue rose 10.6% from $568.3 million a year ago, with gross margin near 96.7% and operating margin around 39.5% as gross profit came to about $608.0 million and operating income reached roughly $248.4 million. Net income increased 14.7% to about $212.1 million from $184.8 million a year earlier, and operating cash flow totaled $559.6 million. The U.S. remained the main revenue contributor at about $578.4 million, Europe climbed 24.2% to roughly $46.0 million, and Japan declined 33.1% to about $4.3 million.

View full earnings history

About Exelixis, Inc.

Exelixis, Inc. is a NASDAQ-listed biotechnology company that develops and commercializes cancer medicines and other therapies, generating $2.3 billion in FY2025 revenue. Its marketed portfolio centers on CABOMETYX tablets, COMETRIQ capsules, and COTELLIC for oncology, alongside MINNEBRO for hypertension, with commercial activity in the United States and Japan.

Name
Exelixis, Inc.
CEO
Michael Morrissey
Website
www.exelixis.com
Industry
Healthcare
Year Founded
1994
Employees
1,077

Today's Snapshot

AI-generated

EXEL closed 1.1% above yesterday's close, while its sector was flat. The day ended with EXEL within 2.3% of its 52-week high of 59.72. Exelixis discussed developing another source of growth at a Citigroup banking summit.

Trading Volume

Below 10d avg (2.0M)

1.7M

vs S&P 500 Today

Outperforming Market

+1.56%

Updated: September 9, 2026 at 20:25 UTC

Technical Indicators

6 Buy2 Neutral0 Sell
EXEL presents a strong-buy profile driven by clear strength across trend and momentum measures: the stock trades well above short- and medium-term averages and remains substantially higher than its 200-day level, while MACD and momentum readings are constructive. Volume-based OBV is supportive of the advance, and volatility is moderate with ATR near $1.60, so moves are orderly rather than erratic. ADX does not show a dominant trend yet, but the alignment of moving averages and positive momentum underpin the bullish score. Technical takeaway: Strong Buy.
All signals
  • EMA (5 indicators)$48.42 - $57.19
    Buy
  • RSI (14)60.36
    Neutral
  • Stochastic %K (14, 3, 3)79.25
    Neutral
  • MACD Level (12, 26)1.16
    Buy

Peers & Related Assets

MRNAModerna, Inc.
$135.61-3.4%
RVMDRevolution Medicines, Inc.
$207.68+0.2%
BBIOBridgeBio Pharma, Inc.
$76.08+1.8%
HALOHalozyme Therapeutics, Inc.
$107.39-0.8%
MDGLMadrigal Pharmaceuticals, Inc.
$546.66+2.3%
BMRNBioMarin Pharmaceutical Inc.
$64.41-0.3%
Stay Ahead of the Market

Get premium market insights delivered directly to your inbox.